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Abstract
Identifying circulating tumor cells (CTCs) with greater sensitivity could facilitate early detection of cancer and rapid
assessment of treatment response. Most current technologies use EpCAM expression as a CTC identifier. However,
given that a significant fraction of cancer patients have low or even absent EpCAM levels, there is a need for better
detection methods. Here, we hypothesize that a multimarker strategy combined with direct sensing of CTC in whole
blood would increase the detection of CTC in patients. Accordingly, molecular profiling of biopsies from a patient
cohort revealed a four-marker set (EpCAM, HER-2, EGFR, and MUC-1) capable of effectively differentiating cancer
cells from normal host cells. Using a point-of-care micro–nuclear magnetic resonance (μNMR) system, we conse-
quently show that this multimarker combination readily detects individual CTC directly in whole blood without the
need for primary purification. We also confirm these results in a comparative trial of patients with ovarian cancer. This
platform could potentially benefit a broad range of applications in clinical oncology.
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Introduction
Tumor biopsies are routinely performed for diagnosis, prognosis,
treatment selection, or, increasingly, for the assessment of treatment
response. However, the cost, morbidity, and measurement intervals
associated with biopsies are often limiting; thus, less invasive alterna-
tives are being examined. For the last few years, circulating tumor cells
(CTCs) have received significant attention as surrogate markers [1–3].
Indeed, emerging evidence suggests that both the absolute number of
CTCs and the changes in their number can serve as prognostic or pre-
dictive markers [4–9]. As a result, more than 300 clinical trials are cur-
rently investigating CTCs in an attempt to correlate their presence and
concentration with treatment outcome (www.clinicaltrials.gov). While
the introduction of commercial kits has facilitated CTC assessment,
their heavy reliance on EpCAM as a single marker has been limiting.
It is generally accepted that EpCAM-based detection has low sensitivity
in EpCAM-negative cancers, which may explain why up to 70% of
patients with metastatic epithelial malignancies fail to exhibit detect-
able CTCs using such methods. This is especially the case for ag-
gressive tumor cells, which often downregulate EpCAM during
epithelial-mesenchymal transition [4]. Such findings underscore the
importance of identifying alternative CTC metrics.
To date, a variety of experimental CTC detection methods have
been described using different biological markers. However, because
most of these methods rely on immunocytochemical or polymerase
chain reaction–based analyses, they often require primary purification
and subsequent skilled processing and interpretation [3]. There is thus
an urgent need to translate cancer-related discoveries into practical clin-
ical and research tools for cancer investigation and treatment. To
achieve this, low-cost strategies that yield robust, quantitative, and fully
objective data within a point-of-care setting are required [10]. Given
that some trials are starting to stratify and tailor patient therapy based
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on CTC changes (clinicaltrials.gov ID: NCT00382018), this is becom-
ing increasingly important.
Here, our aim was to address three central questions in CTC
detection: 1) Can detection be performed directly in whole blood
so as to allow rapid point-of-care use? 2) Can current EpCAM-based
detection paradigms be improved by using a combination of molec-
ular markers? And 3) how much more sensitive would such a method
be when applied to clinical samples? With these questions in mind,
we hypothesized that direct detection of CTCs in whole blood (i.e.,
eliminating the need for primary CTC isolation, during which cells
are often lost) using a multimarker combination would not only
serve to increase detection sensitivity but also would allow detection
within a point-of-care setting.
We investigated this hypothesis in the present study by making
use of a highly sensitive micro–nuclear magnetic resonance (μNMR)
technology that is able to perform cellular profiling directly in whole
blood without the need for cell isolation. Detection was achieved
through the combined and simultaneous sensing of four cancer markers:
EpCAM, HER-2, EGFR, and MUC-1. This new approach, coined
“quad-μNMR,” is fast and can be effectively used in a point-of-care
setting. It also obviates the need for skilled cytology analysis and data
interpretation, a step that is often limiting in busy clinical and labora-
tory environments. Using human blood spiked with cancer cell lines
differentially expressing EpCAM, we show considerably higher CTC
detection rates with quad-μNMR than with other currently used tech-
niques. These findings were later corroborated in a comparative clinical
study of advanced-stage ovarian cancer. The assay’s superior perfor-
mance is particularly evident from its ability to detect EpCAM-negative
(EpCAMneg) cells. The described technology is now poised to enhance
CTC assessment in both preclinical and clinical settings.
Materials and Methods
Cell Culture and Sample Preparation
Tumor cell lines were cultured in flasks according to manufac-
turer’s recommendations and supplemented with 10% fetal bovine
serum (FBS) before subsequent harvesting using trypsin. To determine
cell numbers, a 10-μl aliquot of cells was placed on a hemocytometer
plate, and counts were performed using a conventional inverted micro-
scope. Cells for each experiment were counted in triplicate, and average
values were used as the final spiked value. For experiments using whole
blood, a known number of tumor cells were spiked into 7 ml of whole
blood. For sensitivity experiments, each tube was spiked with 200, 100,
50, and 25 SKBR3 or SKOV3 tumor cells. Whole blood was obtained
from healthy volunteers and placed in tubes containing ethylenediami-
netetraacetic acid (Becton Dickinson, Franklin Lakes, NJ) or into Cell-
Save preservative tubes (Veridex LLC, Raritan, NJ). CTC experiments
using CellSearch to detect spiked cancer cells were conducted at an
independent, outside laboratory blinded to the μNMR results.
Preparation of TCO-Modified Antibodies
Monoclonal antibodies against EpCAM, MUC-1, HER-2, and
EGFR were conjugated with (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-
1-yl carbonate (TCO-NHS), as previously reported (Table W1) [11].
Briefly, the reaction was carried out with 0.5 mg of antibody in
the presence of 1000 equivalents of TCO-NHS in phosphate-buffered
saline (PBS) and 10% dimethylformamide for 3 hours at room
temperature. Unreacted TCO-NHS was then washed using 2 ml of
Zeba desalting columns (Thermo Fisher, Rockford, IL), and antibody
concentrations were determined by absorbance measurement.
Preparation of Tetrazine-Modified Nanoparticles
Cross-linked iron oxide (CLIO) nanoparticles were prepared, and
tetrazine (Tz)-CLIO conjugation was performed (as previously re-
ported [11]) in PBS containing 5% dimethylformamide for 3 hours
at room temperature. Excess Tz-NHS was removed by gel filtration
using Sephadex G-50 (GE Healthcare, Pittsburgh, PA).
Sample Processing and Labeling with
Tz-Modified Nanoparticles
Each whole blood sample (7 ml) was lysed, and the cell pellet was
resuspended in buffer (100 μl of PBS/1% FBS). TCO-modified
monoclonal antibodies (10 μg/ml) were added, and the pellet was
incubated at room temperature for 20 minutes. Samples were then
washed twice, and antibody binding was revealed using magnetic
nanoparticles (100 nM Tz-CLIO) for 10 minutes at room tempera-
ture. Excess Tz-CLIO was removed by washing (centrifugation) twice
in 1 × PBS containing 1% FBS, before being resuspended in 20 μl of
PBS for μNMR measurements. The overall labeling and incubation
procedure took approximately 30 minutes.
Clinical Subjects
μNMR expression profiles from the biopsies of 58 patients with
confirmed epithelial malignancies were obtained as part of an institu-
tional review board–approved study. These patients had been referred
for clinical biopsy of an intra-abdominal lesion after an abnormal
computed tomography or ultrasound, at the Massachusetts General
Hospital Abdominal Imaging and Intervention suites. Also included
were six patients with benign diagnosis, as determined by repeat core
biopsies, imaging [12], and clinical information, as previously de-
scribed [13]. The median age of the malignant cohort was 65 years
(range, 25-91 years). The cancer subtypes consisted of breast (n = 4),
gastrointestinal (n = 17), genitourinary (n = 4), gynecologic (n = 7),
pancreatic (n = 10), lung (n = 9), and poorly differentiated adeno-
carcinoma (n = 7).
Collection of peripheral blood for comparative quad-μNMR and
CellSearch CTC detection was performed using a convenience sam-
ple of 15 patients with ovarian cancer, who were receiving care at the
Gillette Center for Gynecologic Oncology, Massachusetts General
Hospital. The study was approved by the Dana Farber/Partners
Cancer Care Institutional Review Board, and informed consent was
obtained from all participants. Two clinicians (C.M.C. and R.W.),
blinded to the μNMR and CellSearch results, reviewed each subject’s
documented clinical, imaging, and pathology data. Peripheral blood
samples were also obtained from five healthy volunteers.
Design of Experiments
For the present study, our experiments were primarily focused on
1) optimizing the detection conditions, 2) comparing single and multi-
marker detection strategies, and 3) comparing the detection sensitivity
of μNMR to the standard clinical assay, CellSearch.
1) Detection was optimized by examining a variety of different
sample processing and cell fixation procedures. Three aliquots
of SKBR3 cells (14,000, 7000, and 1400 cells) were each spiked
into 7 ml of whole blood in triplicate. HER-2 antibody (10 μg/ml)
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labeling was then performed for each cell concentration experiment
under the following conditions: a) whole blood treated with a red
blood cell (RBC) lysis procedure (Qiagen, Valencia, CA), b) whole
blood treated with a Ficoll density gradient (Miltenyi Biotec,
Auburn, CA) to separate mononucleated cells, and c) whole blood
with no additional processing. The effect of cell fixation was exam-
ined by targeting the HER-2 biomarker in SKBR3 (as described
above); this was done by fixing cells in whole blood either immedi-
ately before or after spiking varying concentrations of SKBR3 cells
(140/ml, 1100/ml, and 6300/ml) into 7 ml of whole blood.
2) To compare single versus multimarker detection, five 7-ml ali-
quots of whole blood were collected from one single healthy in-
dividual for each of 12 experiments. Each blood tube was spiked
with equal and known numbers of cancer cells. The samples were
then processed and distributed into two tubes, one labeled “test”
(containing antibody) and the other labeled control (no antibody).
To each tube designated as “test,” a single aliquot of antibody
against EpCAM, MUC-1, HER-2, or EGFR was added (10 μg/ml),
with the exception of the tube receiving the quad marker (this tube
received antibodies for all four markers). All samples were then pro-
cessed for nanoparticle labeling (100 nM) and analyzed by a single
operator, according to sample preparation and sample analysis pro-
tocols. For each biomarker, the “μNMR Value” was calculated as
the signal obtained from the “test” sample divided by the signal
obtained from the corresponding “control” sample. “μNMR Value”
ratios for both single markers and for the quad marker were obtained
for 12 different cell lines (Figure 2).
3) Detection sensitivity was examined by titration, using varying
numbers of SKBR3 or SKOV3 cells spiked into a whole blood
sample obtained from a healthy donor. The performance of μNMR
was then compared to the standard clinical assay, CellSearch. The
experiment was carried out using a split-sample procedure where
identical samples were processed separately with either μNMR or
CellSearch. The enumeration and identification of tumor cells iden-
tified by CellSearch were performed independently at Brigham and
Woman’s Hospital (Boston, MA). In the quad-μNMR experiment,
cell recovery was calculated based on the number of nanoparticles
detected on the tumor cell surface. In separate validation experi-
ments, bulk cell loss was also assessed by flow cytometry; specifically,
we counted the tumor cells and then used their size and fluorescent
tags to gate and separate the cells from leukocytes (data not shown).
μNMR Measurements
Measurements were conducted using a portable μNMR system re-
cently developed for point-of-care operations [13,14]. The polarizing
magnetic field strength was 0.5 T. The transverse relaxation times were
measured in 1- to 2-μl sample volumes. Carr-Purcell-Meiboom-
Gill pulse sequences with the following parameters were used: echo
time, 3 milliseconds; repetition time, 4 seconds; number of 180°
pulses per scan, 900; number of scans, 7. All measurements were
performed in triplicate, and data are displayed as mean ± standard
error of mean.
Data Analysis and Statistics
T 2 values were obtained in triplicate using the μNMR system. R2
values were calculated as the inverse of the mean T 2 values. The effect
of media in the μNMR readout was accounted for by subtracting the
R2 value of the media (1 × PBS/1% FBS) from either the values ob-
tained from the test (i.e., samples receiving antibody and CLIO for
labeling) or from the control (i.e., samples receiving only CLIO for
background signal determination). The μNMR readout was sub-
sequently calculated by dividing ΔR2
sample by ΔR2
control to account
for any nonspecific binding of CLIO to cells. The μNMR value
served as an expression level of the biomarkers.
Receiver operating characteristic (ROC) analysis was performed
for individual markers and for marker combinations. An Az (area
under the ROC curve) of 0.5 was used to indicate no differences be-
tween two groups, whereas an Az of 1.0 was used to indicate a perfect
separation between the groups. The optimal cutoff value for iden-
tifying malignant status was then defined as the point on the ROC
curve with the minimum distance between the 0% false-negative and
the 100% true-positive.
A paired Student’s t test was used to evaluate the statistical sig-
nificance between the percent cell recovery obtained by μNMR
and that obtained by the CellSearch system. A 2 × 2 contingency anal-
ysis, using the Fisher exact test, was used to evaluate μNMR for its abil-
ity to detect CTCs in whole blood samples from both patients and
healthy controls.
Results
Defining the Detection Signature for Quad-μNMR
The heterogeneous nature of biomarker expression levels is a well-
known phenomenon in cancer, and this served as the rationale for con-
sidering multiple, rather than single, markers for CTC detection. To
begin, we initially obtained samples from a cohort of patients (n = 58)
who had undergone fine needle aspiration of their cancers. These sam-
ples were then profiled for a number of markers including MUC-1,
EGFR, B7-H3, HER-2, Ki-67, EpCAM, Vimentin, CK18, and p53.
Statistical analysis (Spearman correlation and ROC curve) indicated
that diagnostic information (malignant vs benign) could be achieved
by using four key markers: EpCAM, MUC-1, HER-2, and EGFR
(Figure 1). Although analysis of each protein individually revealed that
a notable fraction of the samples were negative for single proteins
(EpCAM, 34.4%; HER-2, 32.7%; MUC-1, 32.7%; and EGFR,
31.0%; Figure 1A), combined marker analysis was able to correctly
identify 99.2% of samples as malignant.
With this information, we developed a μNMR strategy for directly
sensing CTCs in whole blood. This was achieved by first incubating
blood samples with a cocktail of four trans-cyclooctene (TCO)–
labeled antibodies against each protein target, washing the cells,
and then identifying antibody-positive cells using Tz-decorated mag-
netic nanoparticles. This “cocktail” method of targeting cancer cells
not only increases the chances of detecting single marker-negative
patients but also results in much higher magnetic nanoparticle bind-
ing per cell; this leads to increased μNMR signals and better discrim-
ination from background (Figure 1B). The method also eliminates
the need for CTC capture or isolation; instead, CTCs are measured
directly from a pellet of host cells. The nanoparticles also serve as an
amplification strategy, influencing the relaxation times of billions of
surrounding water molecules; these changes can be subsequently
measured by μNMR.
Optimization of μNMR for CTC Detection
Our initial aim was to optimize sample preparation to achieve di-
rect detection of cells in whole blood, while maximizing the μNMR
signal. We thus empirically discovered that cell detection in whole
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blood was best after RBC lysis (Figure W1) and that fixation before
antibody labeling resulted in more reproducible measurements of
CTCs (Figure W2). Next, to compare single-marker versus multi-
marker detection, whole blood samples from a healthy individual were
spiked with 12 different types of epithelial cancer cells representing
a spectrum of EpCAM expression levels (Figure 2). Before μNMR
measurements, each sample was incubated either with a single anti-
body-TCO or with a cocktail containing all four antibody TCOs
(quad marker). From this comparison, we found that the μNMR
signal was highest for the quad marker compared to each single bio-
marker (Figure 2), even in the EpCAM-overexpressing group (e.g.,
SKBR3; Figure 2A). This increase in μNMR values is likely the result
of more efficient nanoparticle binding to cells. Differences in μNMR
signals were particularly pronounced in cell lines lacking (or express-
ing low levels of) EpCAM (e.g., MDA 436, HS578T, BT 549, and
PACA-2; Figure 2, B and C ); these cells showed much higher values
for quad-μNMR than for single EpCAM. This also held true for cell
lines with medium EpCAM expression, which likewise showed higher
μNMR values for quad-μNMR than for single EpCAM. Such a find-
ing has important implications for the detection of CTCs in cancers
with mesenchymal transition or in EpCAMneg cancers.
Detection Sensitivity in Whole Blood
We next performed a series of blinded experiments to determine the
detection sensitivity of CTC in whole blood. Blood samples (7 ml;
similar to clinical CTC protocols) were spiked with known amounts
of cancer cells to achieve a concentration spectrum ranging from
∼30 CTC/ml to 0 CTC/ml. Triplicate samples were then simultaneously
processed for μNMR and CellSearch measurements. The latter mea-
surements were performed independently, in a blinded fashion, in a
clinical service laboratory at an affiliated institution. The detection rates
of quad-μNMR in 7-ml blood samples for different CTC concentra-
tions were as follows: 86/200 spiked cells, 41/100 spiked cells, 18/50
spiked cells, and 8/25 spiked cells (Figure 3A). Overall, the percentage
of tumor cells (number) detected after sample processing ranged from
43% at the higher CTC concentration (∼30 cells/ml) to 32% at the
lower CTC concentration (∼3 cells/ml) with an average rate of 38%
across all concentrations. Figure 3B plots the detection rates against
theoretical values. Using quad-μNMR, we were able to reliably detect
∼3 individual CTCs per sample (in sample volumes ranging from 1 to
10 ml of blood). Furthermore, for all concentrations assessed, quad-
μNMR demonstrated far more sensitive detection of CTCs than single
EpCAM-μNMR (Figure 3B).
We next compared direct μNMR sensing to the clinically approved
CellSearch system. The μNMR assay showed considerably higher
detection sensitivities at all CTC concentrations and for all cell lines
tested. Using CellSearch, the detection rates were, on average, 8.5/
200 spiked cells, 8.5/100 spiked cells, 2.5/50 spiked cells, and 3.5/
25 spiked cells. The percentage of tumor cells recovered thus ranged
from 14% at the 200-cell spike (∼30 cells/ml) to 4.3% at the 25-cell
spike (∼3 cells/ml; Figure 4), and the average recovery rate for
CellSearch was 9.1% across all concentrations. These results demon-
strate that the quad-μNMR detection platform outperforms CellSearch
for all cell concentrations tested (P < .05; Figure 4B).
Figure 1. Clinical rationale and quad-μNMR schematic. (A) Biomarker expression, as assessed by μNMR, showed that a significant
percentage of cancer patients (n = 58) were negative for EpCAM (34.4%), HER-2 (32.7%), MUC-1 (32.7%), or EGFR (31.0%). Combining
these markers, however, enabled identification of nearly all cancer patients (99.2%). (B) Schematic of the quad-μNMR system. TCO-
labeled antibodies are added to whole blood. RBC are then lysed and the cells spun down before reaction with Tz-containing magnetic
nanoparticles. The process of labeling antibodies and targeting nanoparticles requires less than 30 minutes. Biomarker measurements
are then taken using the μNMR device (shown).
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Figure 2. Comparison of single and quad marker detection using μNMR. Quad-μNMR CTC targeting (red bars) in whole blood showed
higher NMR signals than single-marker CTC targeting (blue bars). For comparative purposes, the μNMR values are displayed as relative
ratios. All measurements were obtained in triplicate (note narrow error bars). In all cell lines assessed, quad-μNMR consistently out-
performed all single-μNMR detections. Most notably, quad-μNMR even outperformed EpCAM-μNMR in high- (A), intermediate- (B), and
low/negative- (C) EpCAM-expressing cell lines.
Figure 3. Detection sensitivity of quad-μNMR in whole blood compared with the clinical standard. Varying numbers of cancer cells (i.e.,
200, 100, 50, and 25 cells) were spiked separately into 7-ml samples of blood from a healthy donor. Quad-μNMR measurements are
shown as mean values. Quad-μNMR was able to detect 86/200 spiked cells, 41/100 spiked cells, 18/50 spiked cells, and 8/25 spiked
cells. All μNMR measurements were done in triplicate for both test and control samples. (A) Quad-μNMR outperformed single marker
EpCAM-μNMR for all cell concentrations assessed. (B) Observed values are plotted against theoretical values (gray line).
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Comparative Clinical Study
To determine the clinical utility of the quad-μNMR method, we
conducted a feasibility study in patients with advanced-stage ovarian
cancer (Table 1). We reasoned that given their widespread systemic
disease, these patients were all likely to have CTCs. As a negative
control, we also enrolled 10 normal subjects with no evidence of
cancer. Peripheral blood samples from these subjects were processed
for both quad-μNMR and CellSearch. Figure 5A compares the quad-
μNMR signals from cancer patients with those of normal controls.
Of 15 patients, 13 (87%) showed measurable CTCs by quad-μNMR
(Figure 5, A and B). Average CTC counts (determined with either
quad-μNMR or CellSearch) were higher in more advanced cases
(stage IV, platinum-resistant, and progressive disease) as well as in
patients not undergoing active therapy for various reasons (e.g.,
hospice bound, critical illness). Quad-μNMR was even positive in
patients with nonserous (and presumably less EpCAM-dependent)
histologies (counts, 13-75). Overall, quad-μNMR was found to be
capable of detecting significantly larger numbers of CTC compared
to CellSearch. Indeed, using the standard CellSearch cutoff of five
CTCs or more per 7-ml blood, only one patient (7%) was identified
as CTC positive (Figure 5B); at a cutoff of two CTCs per 7-ml
blood, only three patients (20%) were positive, whereas 87% of
patients were positive by quad-μNMR.
Discussion
Accurate detection and profiling of CTC in blood has been touted as
the “holy grail” in cancer diagnosis. Unfortunately, single marker
(EpCAM)–based detection technologies are not ideal [15]. The US
Food and Drug Administration–approved CellSearch, for instance, re-
lies on signal derived from EpCAM and reportedly misses EpCAMneg
cells [16–18]. Moreover, in the absence of cancer-specific markers, a
systematic analysis of miss rates across large cohorts of patients has been
difficult to obtain. We thus hypothesized that a multimarker detection
paradigm would likely increase cancer cell detection sensitivity. Our re-
sults show that quad marker detection of cancer cells in blood is more
sensitive than conventional EpCAM-based detection, both for μNMR
and for clinical systems (CellSearch). In addition, analysis of cancer cell
lines with variably expressed EpCAM (low, intermediate or high)
served as a better approximate to the clinical reality evident from re-
ported literature [13,19]. For the cell lines tested, and in cells where
EpCAM is present, we show a 400% increase in detection sensitivity
of μNMR over the clinical method. In low-EpCAM-expressing cell
lines, μNMR was even more sensitive. For example, μNMR was found
to be 645%more sensitive in MDA-MB-436, a BRCA1 mutant breast
adenocarcinoma cell line associated with epithelial-mesenchymal
Figure 4. Comparison of quad-μNMR to the clinical standard. (A) Using quad-μNMR detection, the average recovery rate was 38%
across the various cell concentrations assessed (i.e., 200, 100, 50 and 25 spiked cells). Identical experiments performed using the
CellSearch detection system showed an average recovery rate of just 9.1% across all concentrations, ranging from 14% at the 200-cell
spike (∼30 cells/ml) to 4.3% at the 25-cell spike (∼3 cells/ml, i.e., below the five-cell detection threshold recommended by CellSearch).
(B) Compared to the clinically used CellSearch system, quad-μNMR showed higher CTC detection sensitivity (P < .05) for all cell con-
centrations assessed.
Table 1. Summary of Patient Data.
Characteristic Number Percentage CTC by Cell Search,
Mean (Range)
CTC by μNMR,
Mean (Range)
No. patients 15 2 (0-18) 40 (0-170)
Age (years)
Median 62
Range 36-92
Ovarian histology
Serous 10 66 3 (0-18) 48 (0-170)
Endometrioid 1 6.8 0 0
Transitional 1 6.8 0 16
Carcinosarcoma 1 6.8 0 75
Mucinous 1 6.8 0 15
Poorly differentiated 1 6.8 0 13
Stage
IIIC 5 34 1 (0-3) 33 (0-76)
IV 10 66 2 (0-18) 44 (0-170)
Surgical debulking
Optimal 11 73.2 2 (0-18) 41 (0-170)
Suboptimal 3 20 1 (0-4) 45 (18-97)
None 1 6.8 0 13
Median time from diagnosis
(months)
28
Therapy
Active 11 73.2 0.4 (0-3) 27 (0-76)
None 4 26.8 6 (0-18) 76 (19-170)
Platinum
Sensitive 9 60 2 (0-18) 36 (0-170)
Resistant 6 40 1 (0-4) 46 (15-97)
Refractory 0 0 0 0
Disease course
Response 4 26.8 0 8 (0-18)
Stable 3 20 1.3 (0-3) 47 (15-76)
Progression 8 53.2 3 (0-18) 54 (15-170)
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transition and aggressive clinical behavior, which is sensitive to PARP
inhibition [20]. The accurate and timely monitoring of therapy (e.g.,
PARP inhibition)-induced changes in low-EpCAM-expressing CTC
is one specific scenario in which the μNMR approach, if validated in
human trials, could outperform existing CTC detection strategies. This
could lead to improvements in pharmacodynamic assessment for both
cancer drug discovery and clinical research.
There are two novel aspects to the work presented here: a) the use
of μNMR technology for direct measurements of rare cells in whole
blood and b) the preclinical validation of a quadruple CTC marker
signature with promising clinical utility. Prior μNMR iterations using
cancer tissue involved aliquoting parent samples into vials for sequen-
tial analyses of each marker [13]. Here, we were able to optimize the
assay for whole blood analysis by performing RBC lysis and by using a
cocktail of TCO-modified monoclonal antibodies [11]. By subsequently
adding Tz-modified magnetic nanoparticles, which concentrate and
cluster on the cell surface (with additive effects resulting in higher sig-
nals), malignant cells could be readily distinguished from host cells using
magnetic resonance. The μNMR technology could then measure the
presence of these particles in blood with high sensitivity.
In the present study, we tested quad-μNMR in advanced-stage
ovarian cancer patients. Cancer antigen-125 (CA-125) is a protein
that can be elevated in ovarian cancer cells and as such has been used,
although not approved, as a diagnostic cancer marker. The problem
with CA-125, however, is that it is not a reliable indicator of the
disease and thus is not widely recommended for routine testing of
ovarian cancer. As an alternative, CTCs have been identified as novel
and promising biomarkers to improve ovarian cancer diagnosis and
monitoring of treatment response and recurrence. CTCs have been
recently measured in ovarian cancer using the CellSearch method,
and an arbitrary cutoff threshold of two CTCs per 7.5-ml blood
[21,22]. Whereas such studies have underscored the feasibility of
CTC detection and demonstrated a correlation between CTC number
and progression-free survival [22], they have also raised questions re-
garding CTC detection sensitivity. For example, in one recent study
of 216 patients with ovarian cancer, randomized into two chemother-
apy arms, only 14%met the criteria for CTC positivity (more than two
CTCs per 7.5 ml using CellSearch) [22]. To compare the detection
sensitivity of CellSearch with quad-μNMR in the present study, we
focused our experiments on advanced-stage patients who were more
likely to have detectable levels of CTCs. Our results showed that using
the quad-μNMR system, 87% (13/15) of patients had measurable
CTCs, compared to only 7% with the CellSearch system (using the
recommended five-CTCs cutoff; at a two-CTCs cutoff, detection in-
creased to 20%). The only patient positive for CTC using traditional
CellSearch criteria (18 CTCs per sample) was also found to have the
highest CTC levels in the cohort, as assessed using quad-μNMR (170
CTC/sample). All patients with at least one CTC detectable by Cell-
Search (27%) also had detectable CTCs on quad-μNMR. Based on the
preclinical validation presented here, the higher CTC values obtained
by the quad-μNMR technology likely reflect the system’s improved re-
covery of CTCs together with its higher detection sensitivity. TableW2
provides a summary of pertinent clinical information and patient CTC
levels. Although a larger trial is now required to gain further insight
into the clinical potential of the new CTC detection technology, it is
already clear that a strong correlation exists between CTC (as detected
by quad-μNMR) and the clinical scenario, including CA-125 levels.
Quad-μNMR’s superior CTC detection over and above an EpCAM-
based approachmay improve clinicians’ ability to monitor their patients
for tumor response or recurrence.
There are additional advantages to using the μNMR technology
for CTC detection. First, it requires relatively small blood samples
for detection of scant cells. Our experimental data show that we
can reliably and repeatedly detect concentrations of three individual
CTCs per sample. Because these measurements are performed in cell
pellets and in 50- to 100-μl volumes, similar measurements could be
Figure 5. Detection of CTC levels in patient samples using quad-μNMR. (A) CTC levels in the peripheral blood of 15 advanced-stage (IIIC
or IV) ovarian cancer patients compared with those of 10 healthy individuals, as assessed by quad-μNMR. (B) A comparison of CTC
levels in samples determined by either quad-μNMR or CellSearch. A positive result was obtained for 13 of 15 cancer patients using
quad-NMR, whereas only 1 of 15 patients (patient 13) was clearly positive with CellSearch. The dynamic range of CTC levels obtained
using quad-μNMR was 0 to 170.
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performed in both larger blood volumes (to maximize the chance of
detecting rare cells) as well as in blood samples as small as 100 μl.
Using μNMR, we show an average CTC detection rate of 38%; this
percentage is approximately four to six times higher than that
obtained using the CellSearch system. It is likely that this detection
sensitivity could be yet further increased by using nanoparticles with
higher magnetic moments and by continuing to optimize the device.
Second, the portability of the assay is truly point-of-care and readily
adaptable to the clinical scenario. Its modular use (TCO-labeled anti-
bodies) could also be easily modified to include other cancer marker
subsets. The use of this strategy for some targets may be obvious
(TTF-1 for lung cancer, PSMA for prostate cancer populations),
but perhaps the biggest improvement in detection sensitivity will
come from the detection of other emerging targets such as under-
glycosylated and immaturely glycoslyated cancer cells [23], circulating
DNA [24], and/or of unique endothelial cell populations (e.g., breast
cancer patients often have distinct CD34/VEGFR1 populations in
their peripheral circulation). Finally, μNMR represents a platform
technology that could be multiplexed onto chips for the detection
of other diagnostic targets even beyond that of protein markers, for
example, circulating DNA or exosomes. Although these possibilities
were not addressed in the present study, this is an area of ongoing
investigation within our laboratory.
Advances in CTC detection and profiling will undoubtedly con-
tribute to our understanding of human cancer biology. The μNMR
assay in the present study will likely benefit such investigations. A
key remaining question is whether CTC levels and characteristics will
be useful for clinical decision making. The implications of such de-
cisions are not trivial and demand robust and accurate profiling; this
is simply not possible using a single universal marker.
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Table W1. List of Antibodies and Their Associated Characteristics Relevant to the Study.
Marker Clone Species Isotype MW MW (TCO) TCO Valency Company
EpCAM 158206 Mouse IgG2b 150,600 ± 300 152,100 ± 200 9.7 R&D Systems (Minneapolis, MN)
HER2 Trastuzumab Human IgG1 148,700 ± 300 152,300 ± 400 23.2 Genentech (San Francisco, CA)
EGFR Cetuximab Hu/Ms NA 152,400 ± 300 153,800 ± 200 9.2 Imclone Systems (New York, NY)
MUC-1 M01102909 Mouse IgG1 151,900 ± 200 152,600 ± 200 4.8 Fitzgerald Ind. (Acton, MA)
Figure W1. Effect of media on μNMR detection. Three aliquots of
SKBR3 cells (200/ml, 1000/ml, and 2000/ml) were each spiked into
7-ml samples of whole blood. Cancer cells were then targeted us-
ing the HER-2 antibody in untreated whole blood (red line), whole
blood treated with Ficoll (blue line), and whole blood treated with a
RBC lysis procedure (green line). Compared to the other methods,
RBC cell lysis treatment resulted in higher detectable μNMR sig-
nals and was thus adopted for subsequent comparisons.
Figure W2. Effect of fixation on μNMR detection. Three aliquots of
SKBR3 cells (140/ml, 1100/ml, and 6300/ml) were spiked into 7-ml
samples of whole blood for duplicate experiments. In these experi-
ments, cell fixation was done either before (blue line) or after (red
line) labeling with the HER-2 antibody. μNMR data show that cell
fixation before labeling produces better results.
Table W2. Selected Clinical Scenarios Illustrating the Potential Utility of Quad-μNMR.
Clinical Scenario Subject No. CA-125 Cell Search
CTC
Quad-NMR
CTC
Quad Value
Stage IV 8 11 0 15 1.38
11 17 0 13 1.24
6 57 0 16 1.5
7 99 0 75 6.96
2 139 0 19 1.82
1 145 0 0 1.03
5 145 0 18 1.73
15 307 0 15 1.38
12 1123 18 170 15.9
4 1142 4 97 9.09
Progressive disease 14 48 0 17 1.55
6 57 0 16 1.5
7 99 0 75 6.96
2 139 0 19 1.82
15 307 0 15 1.38
12 1123 18 170 15.9
4 1142 4 97 9.09
9 1707 0 19 1.77
Any CellSearch positive 13 136 1 51 4.75
3 895 3 76 7.11
12 1123 18 170 15.9
4 1142 4 97 9.09
